US Bancorp DE Sells 46,944 Shares of Edwards Lifesciences Corporation $EW

US Bancorp DE trimmed its position in Edwards Lifesciences Corporation (NYSE:EW) by 10.2% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 414,455 shares of the medical research company’s stock after selling 46,944 shares during the period. US Bancorp DE’s holdings in Edwards Lifesciences were worth $32,415,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of EW. Brighton Jones LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at $266,000. Farther Finance Advisors LLC lifted its stake in shares of Edwards Lifesciences by 390.7% in the 1st quarter. Farther Finance Advisors LLC now owns 8,808 shares of the medical research company’s stock valued at $633,000 after purchasing an additional 7,013 shares during the period. Pallas Capital Advisors LLC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $222,000. Wealthcare Advisory Partners LLC lifted its stake in shares of Edwards Lifesciences by 5.8% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 7,769 shares of the medical research company’s stock valued at $563,000 after purchasing an additional 429 shares during the period. Finally, Compagnie Lombard Odier SCmA acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $87,000. 79.46% of the stock is currently owned by institutional investors.

Insider Activity at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $74.02 on Friday. The stock has a 50 day moving average price of $78.09 and a 200 day moving average price of $76.10. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a market capitalization of $43.46 billion, a PE ratio of 10.65, a price-to-earnings-growth ratio of 3.61 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the prior year, the firm posted $0.70 earnings per share. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on EW shares. Argus raised Edwards Lifesciences to a “strong-buy” rating in a research note on Thursday, July 10th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday. Evercore ISI set a $88.00 price target on Edwards Lifesciences and gave the company an “outperform” rating in a research note on Tuesday. Morgan Stanley increased their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Finally, Stifel Nicolaus set a $85.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Monday, September 22nd. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $87.06.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.